Targeted Low Dose/Insulin Potentiation Therapy (TLD/IPT) is a non-conventional treatment protocol of cancer based upon the hypothesis that insulin may be used to potentiate the effectiveness of commonly used anti-cancer drugs. Because cancer cells have many more insulin receptors than healthy cells, when exposed to insulin, the cancer cells open these receptors and become more susceptible to low doses of chemotherapeutic agents. The chemotherapeutic agents are then given in much lower doses than in conventional therapies because of this insulin effect. IPT can also deliver chemotherapeutic drugs more frequently, also thought to allow a therapeutic impact, which can be augmented by a synchronic applied hyperthermia, while imparting fewer side effects and allowing patients a higher quality of life.
Conventional chemotherapy tends to flood the body with cytostatics so enough will enter the cancer cells to kill them. Each of our trillions of cells has a membrane, an outer skin, that protects it from toxins. Standard chemotherapy must be given in large enough doses to force penetration through that membrane.
TLD/IPT, however, penetrates easily through the cell membrane because it goes hand-in-hand with sugar (glucose). Cancer cells, unlike healthy cells, need lots of glucose as fuel. Without it, they die. The membrane of a cancer cell is designed to take in a lot more glucose than healthy cells. Cancer cells are equipped with many more insulin receptors. So, if we combine a small dose of chemo drugs with insulin, the cancer cell takes in the cytostatics together we the sugar, which is pushed into the cancer cells by insulin. Using insulin allows us to differentiate the cancer cells from the normal cells. This is a significant advantage. And since the cancer cells are loaded with sugar, they become acidified and become very sensitive to hyperthermia, so that this combination is almost lethal for all kinds of cancers.
As part of our approach to an integrative cancer support and treatment, we may offer, where it is appropriate, targeted low dose chemotherapy in combination with hyperthermia and other biological modulators like high dose vitamin C, phytonutriens like Curcuma, Artemisisn, Green Tea, Indol3Carbinol etc. With the patient’s involvement, assessing the risks and benefits, this promising therapy could change their life.
What are the benefits of Targeted Low Dose Insulin Potentiation Therapy (IPT)?
IPT in combination with hyperthermia can be very tough on tumors, while it is regarded by us to be more gentle for the patient. Patients generally may continue to live a normal lifestyle while being treated.
Using insulin allows us to differentiate the cancer cell population from the normal cell population. That means a lower dose of chemotherapy can be used and this is important since these drugs have considerable toxicity associated with them.
TLD/IPT reduces chemotherapy side effects in normal cells.
The so enhanced chemotherapy’s combined with hyperthermia kills cancer cells more effectively. A 1981 study found that using insulin increased the killing effect of the chemo drug methotrexate by a factor of 10,000, for example [1] and there are also numerous showing, that chemotherapy is augmented by heat.
This gentle treatment allows also the use of complementary therapies to strengthen the immune system, it is our body’s best natural defense against the return of cancer. This treatment costs significantly less than conventional cancer therapies.
TLD/IPT has been used for cancer worldwide since 1946; it has been used in the United States since 1997, hyperthermia is also FDA approved in combination with chemotherapy.
